Skip to main content
  1. Right Decisions
  2. GGC - Clinical Guideline Platform
  3. Gynaecology
  4. Back
  5. Gynaecology guidelines
  6. Preoperative Pregnancy Testing (316)
Announcements and latest updates

Right Decision Service newsletter: April 2024

Welcome to the Right Decision Service (RDS) newsletter for April 2024. 

Issues with RDS and Umbraco access

Tactuum has been working hard to address the issues experienced during the last week. They have identified a series of three mitigation measures and put the first of these in place on Friday 3rd May.  If this does not resolve the problems, the second mitigation will be actioned, and then the third if necessary.

Please keep a lookout for any slowing down of the system or getting locked out. Please email myself, mbuchner@tactuum.com and onivarova@tactuum.com if you experience any problems, and also please raise an urgent support ticket via the Support Portal.

Thank you for your patience and understanding while we achieve a full resolution.

Promotion and communication resources

A rotating carousel presenting some of the key RDS tools and capabilities, and an editable slideset, are now available in the Resources for RDS providers section of the Learning and Support toolkit.

Redesign and improvements to RDS

The redesign of RDS Search and Browse is still on-track for delivery by mid-June 2024. We then plan to have a 3-week user acceptance testing phase before release to live. All editors and toolkit owners on this mailing list will be invited to participate in the UAT.

The archiving and version control functionality is also progressing well and we will advise on timescales for user acceptance testing shortly.

Tactuum is also progressing with the deep linking to individual toolkits within the mobile RDS app. There are several unknowns around the time and effort required for this work, which will only become clear as the work progresses. So we need to be careful to protect budget for this purpose.

New feature requests

These have all been compiled and effort estimated. Once the redesign work is complete, these will be prioritised in line with the remaining budget. We expect this to take place around late June.

Evaluation

Many thanks to those of you completed the value and impact survey we distributed in February. Here are some key findings from the 65 responses we received.

Figure 1: Impact of RDS on direct delivery of care

Key figures

  • 93% say that RDS has improved evidence-informed practice (high impact 62%; some impact 31%)
  • 91% report that RDS has improved consistency in practice (high impact 65%, some impact 26%)
  • 85% say that RDS has improved patient safety (high impact 59%, some impact 26%)
  • Although shared decision-making tools are only a recent addition to RDS, and only represent a small proportion of the current toolset, 85% of respondents still said that RDS had delivered impact in this area (53% high impact, 32% some impact.) 92% anticipate that RDS will deliver impact on shared decision-making in future and 85% believe it will improve delivery of personalised care in future.

Figure 2 shows RDS impact to date on delivery of health and care services

 

Key figures

These data show how RDS is already contributing to NHS reform priorities and supporting delivery of more sustainable care.

Saving time and money

  • RDS clearly has a strong impact on saving practitioner time, with 90% of respondents reporting that this is the case. 65% say it has a high impact; 25% say it has some impact on time-saving.
  • It supports devolved decision-making across the multi-professional team (85% of respondents)
  • 76% of respondents confirm that it saves money compared, for example, to investing in commercial apps (54% high impact; 22% some impact.)
  • 72% believe it has impacted already on saving money and reducing waste in the way services are delivered – e.g. reducing costs of referral management, prescribing, admissions.

Quality assurance and governance

  • RDS leads are clear that RDS has improved local governance of guidelines, with 87% confirming that this is the case. (62% high impact; 25% some impact.)

Service innovation and workforce development

  • RDS is a major driver for service innovation and improvement (83% of respondents) and has impacted significantly on workforce knowledge and skills (92% of respondents – 66% high impact; 26% some impact).

New toolkits

A few examples of toolkits published to live in the last month:

Toolkits in development

Some of the toolkits the RDS team is currently working on:

  • SARCS (Sexual Assault Response Coordination Service)
  • Staffing method framework – Care Inspectorate.
  • SIGN 171 - Diabetes in pregnancy
  • SIGN 158 – British Guideline on Management of Asthma. Selected sections will be incorporated into the RDS, and complemented by a new chronic asthma pathway being developed by SIGN, British Thoracic Society and NICE.
  • Clinical pathways from NHS Fife and NHS Lanarkshire

Please contact his.decisionsupport@nhs.scot if you would like to learn more about a toolkit. The RDS team will put you in touch with the relevant toolkit lead.

Quality audit of RDS toolkits

Thanks to all of you who have responded to the retrospective quality audit survey and to the follow up questions.  We still have some following up to do, and to work with owners of a further 23 toolkits to complete responses. An interim report is being presented to the HIS Quality and Performance Committee.

Implementation projects

Eight clinical services and two public library services are undertaking tests of change to implement the Being a partner in my care app. This app aims to support patients and the public to become active participants in Realistic Medicine. It has a strong focus on personalised, person-centred care and a library of shared decision aids, as well as simple explanations and videoclips to help the public to understand the aims of Realistic Medicine.  The tests of change will inform guidance and an implementation model around wider adoption and spread of the app.

With kind regards

Right Decision Service team

Healthcare Improvement Scotland

Preoperative Pregnancy Testing (316)

Warning

Objectives

To standardise practice in testing for pregnancy in women attending gynaecology

Scope

When to perform pregnancy testing in women undergoing procedures, investigations, treatments and surgical procedures in the inpatient and outpatient setting including those undergoing general anaesthetic

Audience

All Healthcare workers involved in the care of women where pregnancy status would affect care

Please report any inaccuracies or issues with this guideline using our online form

All patients of childbearing potential (biologically female and aged 12-55 years of age) should have pregnancy status determined prior to undergoing anaesthetic, some radiological investigations, surgery under general anaesthetic, or a procedure which may lead to potential disruption of a pregnancy through instrumentation of the uterus.

Pregnancy status should also be determined in women when presenting as an emergency to hospital where pregnancy may determine diagnosis or affect management of these women.

For further details regarding pregnancy testing in girls aged 12-16 years of age, please refer to the RHC guideline Pregnancy testing guidelines for girls aged 12 yrs & over (RHC) 

This guidance is mandatory – every eligible patient must be assessed, every time.

Gaining Consent

NICE suggest that on the day of the procedure or at time of presentation, all women of childbearing potential should have a sensitive discussion as to whether there is any possibility they could be pregnant.  The healthcare professional, should make the patient aware of the risks that both the anaesthetic and the procedure itself can have on the developing pregnancy.

Permission should be sought from the patient to perform the test.  Covert pregnancy testing should not be undertaken as it can be viewed as an infringement of human rights.  Discussions regarding pregnancy testing should be documented in notes.

Routine Urine Pregnancy Testing versus Enquiry Based Assessment

There are two possible options for ascertaining pregnancy status in female patients; consented urine pregnancy testing or Enquiry Based Assessment.

The urine pregnancy test should be considered as first line approach and can be used in conjunction with enquiry based approach.  In cases when urine testing is not possible, practical or feasible, e.g. adults with incapacity, enquiry based assessment alone should be performed and documented.

Information for Enquiry Based assessment includes

  • First day of Last Menstrual Period (LMP)
  • Current contraception and usage
  • Date of last episode of unprotected Sexual Intercourse (UPSI)

The criteria for excluding pregnancy used by the Faculty of Sexual and Reproductive Health is outlined below.

Criteria for excluding pregnancy (adapted from UK Selected Practice Recommendations for Contraceptive Use) 3

Health professionals can be ‘reasonably certain’ that a woman is not currently pregnant if any one or more of the following criteria are met and there are no symptoms or signs of pregnancy: 

  • She has not had intercourse since last normal menses
  • She has been correctly and consistently using a reliable method of contraception
  • She is within the first 7 days of the onset of a normal menstrual period
  • She is not breastfeeding and less than 4 weeks from giving birth
  • She is fully breastfeeding, amenorrhoeic, and less than 6 months’ postpartum
  • She is within the first 7 days post-abortion or miscarriage.

Who should participate in testing?

  • Patient who present to emergency gynaecology services
  • Patients attending for radiological investigations excluding ultrasound
  • Patients undergoing general anaesthetic, including non-gynaecological procedures
  • In the outpatient gynaecology setting, when undertaking procedures where there is instrumentation of the uterus pregnancy status should be determined.  This would include hysteroscopy, pipelle endometrial biopsy, insertion or removal of intrauterine contraceptive devices and LLETZ procedures.
  • Consideration should be given to pregnancy testing prior to administration of hormonal therapies such as contraception or GnRH analogues.

Who is exempt from testing?

The only patients who can be excluded are as follows:

  • Previous total hysterectomy
  • Patients attending for procedure where pregnancy already confirmed e.g. TOP patients, patients management of a miscarriage including MVA and patients undergoing management of ectopic pregnancy

In women where there is contraception use, HRT use and women who are post-menopausal and <55years of age, testing should still be considered and carried out.

How is the test carried out?

Testing should be carried out on the day of the procedure, using a sample collected on admission for the procedure.  High sensitivity urine pregnancy tests should be used which will identify HCG >25iu/l.

The result of the pregnancy test must be recorded in the peri-operative care plan or in the patient notes.  It should include the test kit lot number.

In the theatre setting, the operating surgeon and theatre staff must be informed of any positive result prior to theatre transfer.  The test result, positive or negative, must be included in the surgical pause.

Limitations of Urine pregnancy Testing

It should be acknowledged that the Urine Pregnancy Test adds weight to exclusion of pregnancy, but only if ≥ 3 weeks since UPSI.

Clinicians should consider the risk of becoming pregnant if UPSI < 7 days.  In these cases an assessment should be made with regard to continuing with the planned procedure or rearranging.

Editorial Information

Last reviewed: 23/03/2023

Next review date: 31/03/2028

Author(s): Dr Claire Higgins, Consultant Obstetrics and Gynaecology.

Version: 1

Approved By: Gynaecology Clinical Governance Group

Document Id: 316

References

1. NHSGGC, Pregnancy testing guidelines for girls aged 12 yrs & over (RHC)

2. Routine preoperative tests for elective surgery, NICE guideline, [NG45] Published April 2016

3. Faculty of Sexual and Reproductive Healthcare, Clinical Guidance, Intrauterine Contraception, April 2015, (amended September 2019).

4. Alere TM HCG Casette (25mIU/ML), Product information sheet